(VIANEWS) – OKEA (OKEA.OL), THERMADOR GROUPE (THEP.PA), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. OKEA (OKEA.OL)
33.2% sales growth and 35.99% return on equity
OKEA ASA, an oil and gas company, engages in the development and production of oil and gas in the Norwegian continental shelf. The company holds 44.56% interests in Draugen, 12% interests in Gjøa, 9.2385% interests in Ivar Aasen, 6% interests in Nova, and 15% interests in Yme assets. OKEA ASA was incorporated in 2015 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, OKEA has a trailing twelve months EPS of kr6.79.
PE Ratio
OKEA has a trailing twelve months price to earnings ratio of 4.96. Meaning, the purchaser of the share is investing kr4.96 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.99%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.9%, now sitting on 8.2B for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 1, 2023, the estimated forward annual dividend rate is 4 and the estimated forward annual dividend yield is 10.48%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 76.3% and a negative 56.2%, respectively.
More news about OKEA.
2. THERMADOR GROUPE (THEP.PA)
25.3% sales growth and 19.98% return on equity
Thermador Groupe SA, together with its subsidiaries, engages in the distribution business in France and internationally. The company offers central heating and domestic hot water accessories, pumps for heating, plumbing equipment, taps, valves for building, ventilation equipment and accessories, industrial valves and fittings, cold water pumps, swimming pool equipment and accessories, air compressors, generators, and welding stations. It also provides pneumatic tools; pumps, household valves, and plumbing for DIY superstores; bathroom and kitchen taps for DIY superstores and retail outlets; sale of parts to boiler manufacturers; domestic pumps and pump accessories; accessories and connectors for central heating and domestic water, and plumbing fitments; pipework for the distribution of building fluids; and valves and connectors for building and industry. In addition, the company offers motorised valves and specialty products for industry and air compressors; technical equipment for pressure, temperature, level, and flow measurement and control; and stainless steel connectors, flanges, valves and accessories. Thermador Groupe SA offers its products to retailers, wholesalers in industrial valves and industrial supplies. The company was founded in 1968 and is headquartered in Saint-Quentin-Fallavier, France.
Earnings Per Share
As for profitability, THERMADOR GROUPE has a trailing twelve months EPS of €6.45.
PE Ratio
THERMADOR GROUPE has a trailing twelve months price to earnings ratio of 12.91. Meaning, the purchaser of the share is investing €12.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.98%.
Volume
Today’s last reported volume for THERMADOR GROUPE is 1106 which is 59.42% below its average volume of 2726.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.6%, now sitting on 589.97M for the twelve trailing months.
Moving Average
THERMADOR GROUPE’s value is above its 50-day moving average of €81.03 and below its 200-day moving average of €89.31.
More news about THERMADOR GROUPE.
3. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.19.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.27. Meaning, the purchaser of the share is investing kr32.27 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Moving Average
NAVAMEDIC’s worth is above its 50-day moving average of kr35.15 and above its 200-day moving average of kr36.51.
Volume
Today’s last reported volume for NAVAMEDIC is 102049 which is 168.23% above its average volume of 38045.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.40 at 17:20 EST, way under its 52-week high of kr43.60 and way above its 52-week low of kr29.80.
More news about NAVAMEDIC.
4. HOLLAND COLOURS (HOLCO.AS)
13.8% sales growth and 10.07% return on equity
Holland Colours N.V., together with its subsidiaries, manufactures, distributes, and sells color concentrates in Europe, the Middle East, India, Africa, the Americas, and Asia. The company offers colorants for the building and construction industry, including profiles, pipes, tubing and fittings, siding and cladding, decking, fencing, window blinds, and insulation, as well as solutions for a range of polymers. It also provides colorants for packaging applications comprising water, carbonated soft drinks, fruit juices, dairy, beer, wine, detergents, pharmaceutical, and personal care products. In addition, the company offers coatings, sealants, or adhesives; and colorants for other markets, such as shopping bags, polybags, mulch films, OPP tapes, PU flexible foams, synthetic leather, fiber glass and buttons, paving blocks, artificial stones, cast PMMA, PP non-woven and spunbond, coatings, flexible PVCs, prosthetics, glass fiber reinforced nylon, and silicone rubber and elastomers. It sells its products through a network of agents and distributors. The company was founded in 1979 and is headquartered in Apeldoorn, the Netherlands. Holland Colours N.V. is a subsidiary of Holland Pigments BV.
Earnings Per Share
As for profitability, HOLLAND COLOURS has a trailing twelve months EPS of €6.75.
PE Ratio
HOLLAND COLOURS has a trailing twelve months price to earnings ratio of 13.78. Meaning, the purchaser of the share is investing €13.78 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.07%.
Moving Average
HOLLAND COLOURS’s value is under its 50-day moving average of €101.25 and way below its 200-day moving average of €115.04.
Sales Growth
HOLLAND COLOURS’s sales growth is 13.8% for the current quarter and 13.8% for the next.
Volume
Today’s last reported volume for HOLLAND COLOURS is 241 which is 35.39% above its average volume of 178.
Revenue Growth
Year-on-year quarterly revenue growth declined by 13%, now sitting on 111.44M for the twelve trailing months.
More news about HOLLAND COLOURS.
5. ITERA (ITERA.OL)
12.4% sales growth and 97.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.79.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 15.7. Meaning, the purchaser of the share is investing kr15.7 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 97.07%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 831.86M for the twelve trailing months.
Volume
Today’s last reported volume for ITERA is 282 which is 98.79% below its average volume of 23342.
Sales Growth
ITERA’s sales growth is 11.8% for the current quarter and 12.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ITERA’s EBITDA is 1.29.
More news about ITERA.
6. MELEXIS (MELE.BR)
11% sales growth and 43.81% return on equity
Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, latch and switch, current, inductive position, tire monitoring, temperature, optical, pressure, and speed sensor ICs. It also offers embedded motor driver, fan and pump, LED, and pre driver ICs; and LIN transceiver, CAN transceiver, RFID Transceiver NFC Sensor tag ICs. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.
Earnings Per Share
As for profitability, MELEXIS has a trailing twelve months EPS of €5.04.
PE Ratio
MELEXIS has a trailing twelve months price to earnings ratio of 16.5. Meaning, the purchaser of the share is investing €16.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.81%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.6%, now sitting on 908.94M for the twelve trailing months.
More news about MELEXIS.
7. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.32.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 71.88. Meaning, the purchaser of the share is investing kr71.88 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr23.00 at 17:20 EST, under its 52-week high of kr25.10 and way higher than its 52-week low of kr11.25.
More news about VISTIN PHARMA.
8. AXACTOR (ACR.OL)
5.2% sales growth and 9.72% return on equity
Axactor ASA, through its subsidiaries, operates as a debt management and collection company in Sweden, Finland, Germany, Italy, Norway, and Spain. It operates through two segments: Non-performing Loans and Third-Party Collection. The Non-performing Loans segment invests in portfolios of non-performing loans collected through amicable or legal proceedings. The Third-Party Collection segment provides debt collection services on behalf of third-party clients, which applies amicable and legal proceedings to collect the non-performing loans. This segment is also involved in helping creditors to prepare documentation for future legal proceedings against debtors; and handling of invoices between the invoice date and the default date and sending out reminders. Axactor ASA was incorporated in 1982 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, AXACTOR has a trailing twelve months EPS of kr1.71.
PE Ratio
AXACTOR has a trailing twelve months price to earnings ratio of 3.09. Meaning, the purchaser of the share is investing kr3.09 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.72%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
AXACTOR’s EBITDA is 989.79.
Sales Growth
AXACTOR’s sales growth is 21.2% for the current quarter and 5.2% for the next.
More news about AXACTOR.
